The Oncology Brothers Highlight Three Studies from AACR 2023

The Oncology Brothers highlight three studies from the recent American Association for Cancer Research (AACR) 2023 Annual Meeting, each centered around a different disease site. In this segment, they detail: The AEGAN study, which focused on resectable, non-small cell lung cancer patients; the KEYNOTE-966 study, a Phase III trial on patients with unresectable, locally advanced extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer; and the SWOG S1512, a study on desmoplastic melanoma, which the duo noted as having “encouraging” results. All three studies have the potential to impact the oncology community setting.